Ceftobiprole (BAL9141) is an investigational cephalosporin with broad in vitro activity against Gram-positive cocci including enterococci. Ceftobiprole minimal inhibitory concentrations (MICs) were determined for 93 isolates of E. faecalis (including 16 β-lactamase (Bla) producers and 17 vancomycin-resistant isolates) using an agar dilution method following the CLSI recommendations. Ceftobiprole MICs were also determined using a high inoculum (10 7 CFU/ml) for a subset of five Bla+ producers belonging to different previously characterized clones using a broth dilution method. Time-kill and synergism studies (with either streptomycin or gentamicin) were performed using two β-lactamase producing isolates (TX0630 and TX5070) and two vancomycin-resistant isolates (TX2484, VanB and TX2784, VanA). The MIC 50/90's of ceftobiprole were 0.25 µg/ml and 1 µg/ml, respectively. All Bla-producers and vancomycin-resistant isolates were inhibited by concentrations of < 1 and < 4 µg/ml, respectively, at standard inoculum. Ceftobiprole MICs at high inoculum for a subset of five Bla+ E. faecalis were < 1 µg/ml. Bactericidal activity was observed for 4 isolates tested at concentrations as low as 1 µg/ml regardless of the production of β-lactamase or vancomycin resistance. The combination of ceftobiprole (0.5 µg/ml) and streptomycin (25 µg/ml) was synergistic against Bla+ TX0630 and TX5070. Ceftobiprole (0.5 µg/ml) plus gentamicin (10 µg/ml) was synergistic against the VanB isolate TX2484, and showed enhanced killing, but not synergism against TX2784 (VanA), despite absence of high level resistance to gentamicin. In conclusion, ceftobiprole exhibited good in vitro activity against E.
INTRODUCTION
Enterococcal infections continue to be a challenge in clinical practice due to the fact that these organisms have the ability to quickly acquire and disseminate resistance genes. The introduction of new agents into clinical practice (e.g. linezolid and daptomycin, amongst others) has been shortly followed by the development of resistance (10) . Furthermore, the treatment of certain enterococcal infections (e.g., endocarditis) requires the use of bactericidal (14) agents which decrease even further the choice of antimicrobials.
Ceftobiprole (BPR) is a novel broad-spectrum parenteral cephalosporin with high affinities for Gram-negative and Gram-positive penicillin-binding proteins (PBPs), including PBP 2a from methicillin-resistant Staphylococcus aureus (MRSA) (2, 6) and PBP 2X from resistant pneumococci (5, 11) . The in vitro spectrum of activity includes both Gram-positive and Gram-negative organisms, including S. aureus (both MRSA and MSSA isolates) (2, 7), pneumococci (including penicillin and ceftriaxone resistant isolates) (5) , Streptococcus pyogenes and other streptococci (11), Haemophilus influenzae and Moraxella catarrhalis (including β-lactamase producers) (1) producing isolate) and Porphyromonas somerae (9) , although Bacteroides fragilis group isolates have been found to be resistant (9, 23) .
Against enterococci, BPR was reported to have in vitro bactericidal activity against most strains of ampicillin and vancomycin-susceptible Enterococcus faecalis with MIC 50 /MIC 90 values of 0.5 and 4 µg/ml for a small collection of E. faecalis isolates (6, 11). BPR exhibited bactericidal activity at concentrations of 4, 8 and 16 µg/ml using an ampicillin and vancomycin-susceptible E. faecalis isolate (E. faecalis ATCC 29212) (6).
Time-kill studies failed to show synergism when ceftobiprole (8 µg/ml) was combined with gentamicin (at ¼ MIC) against two clinical isolates of E. faecalis (ampicillin and vancomycin-susceptible) (6). When tested against ampicillin-susceptible E. faecium, the BPR MIC 90 value was 8 µg/ml (11), but it lacked activity against ampicillin-resistant E. faecium (6, 11).
The objective of this work was to evaluate the in vitro activity of BPR against a larger collection of E. faecalis isolates and use time-kill curves and synergism studies (with aminoglycosides) to specifically assess ceftobiprole bactericidal activity against β-lactamase producing (Bla+) and vancomycin-resistant isolates. 
A C C E P T E D

MATERIALS AND METHODS
Bacterial strains. A total of 93 isolates of E. faecalis were included in the study. They were isolated from five different countries (USA, Chile, Argentina, Lebanon and Thailand) and the majority of the isolates were obtained from patients' clinical samples (mainly blood from endocarditis and non-endocarditis patients and urine). The collection included 17 vancomycin resistant isolates and 15 β-lactamase producing E. faecalis. The Bla+ isolates had previously been characterized by pulsed field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) (17) and confirmation of β-lactamase activity was performed with nitrocefin disks following the Clinical Laboratory Standards Institute (CLSI) recommendations (3). Isolates obtained from fecal samples of healthy volunteers (2 isolates), animals and animal feed (7 isolates) and laboratory strains (E. faecalis JH2-2 (12) and OG1RF (16) were also included in the study. All isolates were kept at -80 C and recovered from frozen stocks. Susceptibilities of isolate TX5070 (a Bla+ transconjugant of E. faecalis JH2-7 (Table 1) , which is a thymine auxotroph and cannot grow on Mueller-Hinton) (12), were performed on brain heart infusion (BHI) agar with a starting inoculum of 10 4 CFU/spot. For selected (4)) and TX5070 (a laboratory strain obtained in a mating experiment between the first ever discovered Bla+ enterococcal isolate (E. faecalis HH22, used as donor) (15) and E.
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faecalis JH2-7 (a thymine auxotroph) (12)) and the vancomycin-resistant, ampicillinsusceptible isolates TX2484 and TX2784. Bacteria were grown in flasks at a final volume of 20 ml in BHI broth with a starting inoculum of 10 7 CFU/ml from an overnight culture.
Ceftobiprole was added at concentrations of 1 and 2 µg/ml for time-kill curves and 0.5 µg/ml for synergism studies which are below the therapeutic levels achieved in humans (22) . The concentrations of aminoglycosides used in the synergy studies were below the MIC of the organisms and produced no significant growth inhibition in the absence of ceftobiprole. Concentrations of gentamicin 10 µg/ml and streptomycin 25 µg/ml were found to yield the best killing activity. Viable counts were determined at times 0, 4 and 24 h by plating appropriate dilutions of the cultures on BHI agar plates. Antibiotic carryover was eliminated by centrifuging 1 ml samples of the culture and resuspending
on August 29, 2017 by guest http://aac.asm.org/ Downloaded from the pelleted bacteria in 0.9% saline before plating. Time-kill and synergism studies were performed from 2 to 4 times per strain. The level of detection was 10 CFU/ml assuming maximum plating efficiency. Bactericidal activity was defined as > 3-log 10 decrease in CFU/ml between counts at time 0 h and those observed at time 24 h. Synergism was defined as a > 2 log 10 -decrease in CFU/ml between the combination of ceftobiprole plus aminoglycosides (gentamicin or streptomycin) and ceftobiprole alone at 24 h, with a concentration of the aminoglycoside that did not affect the growth curve of the test organism when used alone.
RESULTS
Ceftobiprole MICs. The BPR MIC distribution of all isolates including the subgroups of vancomycin-resistant and Bla+ isolates is shown in Figure 1 . The BPR MIC 90 and MIC 50 for all isolates were 1 µg/ml and 0.25 µg/ml, respectively, ranging from <0.015 to 4 µg/ml. The presence of vancomycin resistance did not influence BPR susceptibility: 94% of vancomycin resistant isolates had MICs of ceftobiprole < 1 µg/ml. Among the 16 β-lactamase producers, the BPR MIC 100 was 1 µg/ml. Table 2 shows the BPR MICs for a subset of five β-lactamase producers from different clonal origins at two inocula. The use of a high inoculum (10 7 CFU/ml) for MIC determination in broth for these isolates resulted in an increase of 2 to 8 fold in the MIC but all MIC's were of < 2 µg/ml (Table   2) . A similar increase occurred in isolates TX2484 and TX2784 lacking the β-lactamase enzyme (2 and 4 fold increase in MIC at high inoculum). µg/ml were bactericidal against both Bla+ strains, decreasing the viable bacterial count (CFU/ml) ca. 4 log 10 from the starting inoculum (time 0) (Fig. 2 ). Fig. 3 shows that ceftobiprole was also bactericidal against vancomycin resistant isolates. For both TX2484
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(a VanB isolate) and TX2784 (a VanA isolate), BPR decreased the viable counts > 3 log 10 CFU/ml at 24 h from the starting inoculum.
Synergism between ceftobiprole and aminoglycosides. The synergistic activity of aminoglycosides (either gentamicin or streptomycin) was evaluated for two Bla+ and two vancomycin resistant E. faecalis isolates. For the Bla+ strains (which exhibit high level resistance to gentamicin but not streptomycin), the addition of streptomycin (25 µg/ml) to ceftobiprole was synergistic (Fig. 2) . The decrease in viable counts (CFU) at 24 h was > 2 log 10 (ca. 3 log 10 for TX0630 and ca. 4 log 10 for TX5070 when compared with ceftobiprole alone) ( Fig. 2A and 2B) . Similarly, the combination of ceftobiprole and gentamicin (10 µg/ml) was synergistic against the vancomycin-resistant isolate TX2484
( Fig. 3A) (reduction of ca. 2.5 log 10 CFU/ml when gentamicin was added compared to ceftobiprole alone). The addition of gentamicin (10 µg/ml) for isolate TX2784 decreased counts by less than 2 log 10 CFU/ml at 24 h (Fig. 3B) . The lack of synergism in strain TX2784 was observed at concentrations of 0.25, and 1 µg/ml of ceftobiprole and using concentrations of gentamicin of 5 and 8 µg/ml (data not shown).
DISCUSSION
Ceftobiprole is a novel cephalosporin that has been shown to be active against Grampositive organisms (including MRSA) and also maintains the spectrum of extended spectrum cephalosporins against Gram-negative bacteria (2, 11). The basis for ceftobiprole's potent activity against many organisms is its high affinity for penicillin binding proteins (including PBP2a of MRSA) and stability against hydrolysis by β-lactamases (11). Against enterococci, ceftobiprole displays unique properties amongst the cephalosporins, since it has good activity against isolates of E. faecalis (6). A previous study (11) showed that the MIC 90 for a collection of 14 clinical isolates of ampicillinsusceptible E. faecalis was 4 µg/ml. The results of our work support the potent in vitro activity of ceftobiprole against E. faecalis from different geographical, clinical and host origins (MIC 90 of 1 µg/ml for our isolates). Furthermore, our findings confirm that susceptibility to ceftobiprole in E. faecalis is not affected by the presence of vancomycin resistance or by β-lactamase production in enterococci. Although a modest inoculum effect was seen with ceftobiprole for both Bla+ and Bla _ isolates, the MIC remained < 2 µg/ml.
We also evaluated the bactericidal activity of ceftobiprole against four strains of E.
faecalis exhibiting either vancomycin resistance (VanA and VanB phenotypes, Table 1 ) the blaZ gene (15) , and ceftobiprole is a poor substrate of these enzymes which explains its excellent activity against β-lactamase producing E. faecalis.
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The combination of β-lactams and aminoglycosides has been widely used in the treatment of enterococcal infections that require bactericidal therapy for optimal cure rates (e.g., endocarditis) (14) . Previously, no synergistic activity was observed for two strains of E.
faecalis when using concentrations of ceftobiprole of 8 µg/ml and gentamicin at ¼ of the MIC of the strains (6). In contrast with these data, we were able to demonstrate synergism in 3 out of 4 isolates of E. faecalis when using concentrations of ceftobiprole of 0.5 µg/ml (which is at MIC value or slightly higher). An explanation for this discrepancy is that, at concentrations of ceftobiprole as high as 8 µg/ml (as used by Deshpande et al. (6)), the killing effect of ceftobiprole is so marked that it may mask the effect of the aminoglycoside. Consistent with this hypothesis is the fact that we were unable to show any synergism when using concentrations of 1 µg/ml, 2 µg/ml and 4 µg/ml of ceftobiprole (data not shown).
Synergistic activity was evident in the presence of β-lactamase in different host backgrounds. Both TX0630 (a Bla+ clinical strain) and TX5070 (a Bla+ laboratory strain) exhibited synergism when ceftobiprole was combined with streptomycin at concentrations of 25 µg/ml. Both isolates have HLR to gentamicin but not to streptomycin. Similarly, the combination of ceftobiprole (0.5 µg/ml) and gentamicin (10 µg/ml) was synergistic against one vancomycin-resistant (VanB) isolate of E. faecalis.
However, although a decrease in viable counts by the combination of ceftobiprole and
on August 29, 2017 by guest http://aac.asm.org/ Downloaded from gentamicin compared to ceftobiprole alone was observed at 24 h in isolate TX2484 (a VanA human fecal isolate from Spain), the reduction in CFU/ml did not reach the cut-off for synergism (> 1 log 10 but < 2 log 10 ). These results indicate that, with selected isolates of Bla+ or vancomycin-resistant E. faecalis, the combination of ceftobiprole and aminoglycosides could be potentially useful in clinical settings where bactericidal therapy is important. In vivo studies will be of paramount importance to clarify this issue.
As opposed to E. faecalis isolates, E. faecium have developed different strategies for β-lactam resistance which include the hyperproduction of PBP5 which has low affinity for β-lactams and is capable of substituting for the functions of β-lactam susceptible PBPs (8) and by introducing amino acid substitutions in the penicillin-binding domain of PBP5 (13, 20, 24) . Previous studies (6) have shown that ceftobiprole had no activity against ampicillin-resistant E. faecium indicating that it is likely that the ceftobiprole affinity for the PBP5 of E. faecium is low and therefore not clinically useful for the treatment of ampicillin-resistant E. faecium infections.
In conclusion, we demonstrated that ceftobiprole has potent in vitro activity against the largest collection of E. faecalis tested to date. The activity was not affected by vancomycin-resistance or production of β-lactamase and synergism with aminoglycosides can be achieved in selected strains. Therefore, ceftobiprole emerges as a promising agent with potential for future use to treat Bla+ and vancomycin-resistant E. faecalis infections. c Using either gentamicin 10 µg/ml or streptomycin 25 µg/ml when appropriate BPR, ceftobiprole; AMP, ampicillin; VAN, vancomycin; GEN, gentamicin; STR, streptomycin d > 1 log 10 but < 2 log 10 decrease in CFU/ml vs BPR at 24 h. 
